Sfoglia per AUTORE
CHEREPANOV D
Collezione AOU Città della Salute di Torino
Items : 2
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):491-504. doi: 10.1016/j.clml.2023.03.007. Epub 2023 Mar 2
2023
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Cain LE; Manne S; Rajkumar SV; Cherepanov D; Wang B; Vorog A; Labotka RJ; C de Farias DL; Min CK; Grosicki S; Benjamin R; Pour L; Bringhen S; Dimopoulos MA;
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. in Annals of hematology / Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10.
2021
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Zonder J; Boccadoro M; Thompson M; Weisel K; Berdeja J; Lee HC; Leleu X; Huang H; Stull DM; Cherepanov D; Terpos E; Hajek R; Romanus D; Palumbo A; Abonour R; Usmani S; Morgan G; Costello C; Rifkin R; Davies F; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A;